Insights from Clinical Trials: Evidence-Based Recommendations for Induction Treatment of Newly Diagnosed Transplant-Eligible Multiple Myeloma
Olga Lytvynova(Cleveland Clinic), Faiz Anwer(Cleveland Clinic), Shahzad Raza(Cleveland Clinic), Jenna Jwayyed(Indiana University – Purdue University Indianapolis), Sandra Mazzoni(Cleveland Clinic), Daniel Pastel(Cleveland Clinic), Jack Khouri(Cleveland Clinic), Louis O. Williams(Cleveland Clinic), Rohan Prasad(Cleveland Clinic)
Cited by 4
Related Papers
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
|Nature Medicine|2023|239
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel
|Journal of Hematology & Oncology|2024|46
The Cleveland Clinic experience of eosinophilic myocarditis in the setting of hypereosinophilic syndrome: demographics, cardiac imaging, and outcomes
|Cardiovascular Diagnosis and Therapy|2024|5